.

Karyopharm Therapeutics reported $242.45M in Current Assets for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Amgen AMGN:US $ 19322M 802M
AstraZeneca AZN:LN 20.92B 1.73B
Astrazeneca AZN:US 20.92B 1.73B
Avrobio Inc AVRO:US 142.08M 28.84M
Bristol Myers Squibb BMY:US $ 30186M 65M
Eli Lilly And LLY:US $ 17115.2M 150.5M
Enanta Pharmaceuticals ENTA:US $ 313.04M 28.83M
Epizyme EPZM:US $ 186.84M 41.87M
GlaxoSmithKline GSK:LN 5418.8B 2520B
Karyopharm Therapeutics KPTI:US $ 242.45M 34.09M
Macrogenics MGNX:US $ 167.63M 50.57M
Mirati Therapeutics MRTX:US $ 1202.93M 140.19M
Nektar Therapeutics NKTR:US $ 665.54M 67.92M
Novartis NOVN:VX 38.14B 906M
Novartis NVS:US $ 38142M 906M
Regeneron Pharmaceuticals REGN:US $ 15529.9M 1223.9M
Sangamo Biosciences SGMO:US $ 343.12M 3.06M
Takeda 4502:JP Y 2549515M 44127M
Ultragenyx Pharmaceutical RARE:US $ 678.54M 28.98M
Xencor XNCR:US $ 585.94M 79.97M
YTE INCY:US $ 3625.84M 337.75M